AbbVie Inc. Files 8-K: Director Changes and Shareholder Votes

Ticker: ABBV · Form: 8-K · Filed: 2025-05-13T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, officer-changes, shareholder-vote

Related Tickers: ABBV

TL;DR

AbbVie's 8-K shows director changes and upcoming shareholder votes.

AI Summary

On May 8, 2025, AbbVie Inc. filed an 8-K report detailing several key events. The filing includes information regarding the departure and election of directors, the appointment of certain officers, and updates to compensatory arrangements for officers. Additionally, it covers the submission of matters to a vote of security holders, indicating potential shareholder decisions on corporate matters.

Why It Matters

This filing provides crucial updates on AbbVie's corporate governance and potential shareholder decisions, which can impact investor confidence and strategic direction.

Risk Assessment

Risk Level: low — The filing primarily concerns corporate governance and procedural matters, with no immediate financial distress or significant operational changes indicated.

Key Players & Entities

FAQ

What specific changes occurred regarding AbbVie's directors and officers?

The 8-K filing indicates the departure of certain directors and officers, as well as the election of new directors and the appointment of certain officers.

What types of compensatory arrangements were updated for officers?

The filing mentions updates to compensatory arrangements for certain officers, but specific details of these arrangements are not provided in the summary information.

What matters were submitted to a vote of security holders?

The filing states that matters were submitted to a vote of security holders, but the specific nature of these matters is not detailed in the provided text.

What is the primary purpose of this 8-K filing for AbbVie?

The primary purpose is to report significant corporate events including changes in directors and officers, and matters submitted for shareholder vote, as required by SEC regulations.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on May 8, 2025.

From the Filing

0001104659-25-047402.txt : 20250513 0001104659-25-047402.hdr.sgml : 20250513 20250512175855 ACCESSION NUMBER: 0001104659-25-047402 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250508 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250513 DATE AS OF CHANGE: 20250512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 25936422 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 tm2513856d1_8k.htm FORM 8-K false 0001551152 0001551152 2025-05-08 2025-05-08 0001551152 us-gaap:CommonStockMember exch:XNYS 2025-05-08 2025-05-08 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2025-05-08 2025-05-08 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2025-05-08 2025-05-08 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2025-05-08 2025-05-08 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2025-05-08 2025-05-08 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2025-05-08 2025-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549     FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): May 8, 2025   ABBVIE INC. (Exact name of registrant as specified in its charter)   Delaware   001-35565   32-0375147 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)         1 North Waukegan Road North Chicago , Illinois 60064-6400 (Address of principal executive offices)(Zip Code)    Registrant’s telephone number, including area code: ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange         NYSE Texas 0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange 2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange 2.625% Senior Notes due 2028   ABBV28B   New York Stock Exchange 2.125% Senior Notes due 2029   ABBV29   New York Stock Exchange 1.250% Senior Notes due 2031   ABBV31   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨  

View on Read The Filing